Antiangiogenic Resistance and Cancer Metabolism: Opportunities for Synthetic Lethality

Area of Science:

• Oncology
• Cancer Metabolism
• Drug Resistance

Background:

• Antiangiogenic therapy is crucial for cancer treatment but faces significant resistance.
• Compensatory proangiogenic pathways emerge upon vascular endothelial growth factor inhibition, complicating combination therapies due to toxicity.
• Aberrant cancer metabolism, including altered glycolysis and glutaminolysis, presents a potential therapeutic vulnerability.

Purpose of the Study:

• To explore a novel therapeutic approach by combining antiangiogenics with agents targeting aberrant cancer metabolism.
• To investigate the concept of induced essentiality or contextual lethality by inhibiting metabolic pathways that become vital under antiangiogenic treatment.
• To address the challenges posed by interpatient and intratumor heterogeneity in metabolic profiles.

Main Methods:

• Preclinical investigation of compensatory proangiogenic pathways.
• Analysis of distinct cancer cell metabolic features compared to normal cells.
• Exploration of synthetic lethality by combining antiangiogenics with metabolic inhibitors.

Main Results:

• Antiangiogenics can disrupt cancer's ability to sustain aberrant metabolism, potentially inducing synthetic lethality.
• Specific metabolic pathways may become essential for tumor survival when targeted in combination with antiangiogenics.
• Interpatient and intratumor heterogeneity in metabolism presents a significant challenge for personalized treatment.

Conclusions:

• Targeting cancer metabolism in combination with antiangiogenics offers a promising strategy to overcome drug resistance.
• Understanding and dynamically tracking tumor metabolism is key to tailoring combination therapies.
• Window-of-opportunity designs integrating metabolic tracking could personalize antiangiogenic treatment strategies.